323 related articles for article (PubMed ID: 33658570)
1. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
[TBL] [Abstract][Full Text] [Related]
2. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.
Azad TD; Jin MC; Bernhardt LJ; Bettegowda C
Neurosurg Focus; 2020 Jan; 48(1):E9. PubMed ID: 31896079
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
5. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
Panditharatna E; Kilburn LB; Aboian MS; Kambhampati M; Gordish-Dressman H; Magge SN; Gupta N; Myseros JS; Hwang EI; Kline C; Crawford JR; Warren KE; Cha S; Liang WS; Berens ME; Packer RJ; Resnick AC; Prados M; Mueller S; Nazarian J
Clin Cancer Res; 2018 Dec; 24(23):5850-5859. PubMed ID: 30322880
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy in H3K27M diffuse midline glioma.
Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
[TBL] [Abstract][Full Text] [Related]
7. Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.
Bruzek AK; Ravi K; Muruganand A; Wadden J; Babila CM; Cantor E; Tunkle L; Wierzbicki K; Stallard S; Dickson RP; Wolfe I; Mody R; Schwartz J; Franson A; Robertson PL; Muraszko KM; Maher CO; Garton HJL; Qin T; Koschmann C
Clin Cancer Res; 2020 Dec; 26(23):6266-6276. PubMed ID: 33087334
[TBL] [Abstract][Full Text] [Related]
8. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
[TBL] [Abstract][Full Text] [Related]
9. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
[TBL] [Abstract][Full Text] [Related]
10. [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors].
Natsumeda M; On J; Watanabe J; Tsukamoto Y; Okada M; Fujii Y; Adachi J; Nishikawa R
No Shinkei Geka; 2021 May; 49(3):527-534. PubMed ID: 34092558
[TBL] [Abstract][Full Text] [Related]
11. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
12. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
13. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
14. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Valpione S; Campana L
Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
[TBL] [Abstract][Full Text] [Related]
16. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
bioRxiv; 2024 May; ():. PubMed ID: 38798502
[TBL] [Abstract][Full Text] [Related]
17. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4.
Mo Y; Duan S; Zhang X; Hua X; Zhou H; Wei HJ; Watanabe J; McQuillan N; Su Z; Gu W; Wu CC; Vakoc CR; Hashizume R; Chang K; Zhang Z
Cancer Discov; 2022 Dec; 12(12):2906-2929. PubMed ID: 36305747
[TBL] [Abstract][Full Text] [Related]
18. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract][Full Text] [Related]
19. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
20. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]